Literature DB >> 12115821

Factors affecting the deposition of inhaled porous drug particles.

Cynthia J Musante1, Jeffry D Schroeter, Jacky A Rosati, Timothy M Crowder, Anthony J Hickey, Ted B Martonen.   

Abstract

Recent findings indicate that the inhalation of large manufactured porous particles may be particularly effective for drug delivery. In this study, a mathematical model was employed to systematically investigate the effects of particle size, particle density, aerosol polydispersity, and patient ventilatory parameters on deposition patterns of inhaled drugs in healthy human lungs. Aerodynamically similar particles with densities of 0.1, 1.0, and 2.0 g/cm(3) were considered. Particle size distributions were defined with mass median aerodynamic diameters (MMADs) ranging from 1 to 3 microm and geometric standard deviations ranging from 1.5 to 2.5, representing particles in the respirable size range. Breathing rates of 30 and 60 L/min with tidal volumes of 500 to 3000 mL were assumed, simulating shallow to deep breaths from a dry powder inhaler. Particles with a high density and a small geometric diameter had slightly greater deposition fractions than particles that were aerodynamically similar, but had lower density and larger geometric size (typical of manufactured porous particles). This can be explained by the fact that particles with a small geometric diameter deposit primarily by diffusion, which is a function of geometric size but is independent of density. As MMAD increased, the effect of density on deposition was less pronounced because of the decreased efficiency of diffusion for large particles. These data suggest that polydisperse aerosols containing a significant proportion of submicron particles will deposit in the pulmonary airways with greater efficiency than aerodynamically similar aerosols comprised of geometrically larger porous particles. Copyright 2002 Wiley-Liss Inc. and the American Pharmaceutical Association J Pharm Sci 91:1590-1600, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115821     DOI: 10.1002/jps.10152

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  Size mapping of electric field-assisted production of polycaprolactone particles.

Authors:  M Enayati; Z Ahmad; E Stride; M Edirisinghe
Journal:  J R Soc Interface       Date:  2010-06-02       Impact factor: 4.118

2.  A geometrical approach to the PKPD modelling of inhaled bronchodilators.

Authors:  Claudio Gaz; George Cremona; Simona Panunzi; Beverley Patterson; Andrea De Gaetano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-17       Impact factor: 2.745

Review 3.  Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.

Authors:  Darren Michael Moss; Marco Siccardi
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

4.  Inhalable Nano-Dimpled Microspheres Containing Budesonide-PLGA for Improved Aerodynamic Performance.

Authors:  Chang-Soo Han; Ji-Hyun Kang; Young-Jin Kim; Dong-Wook Kim; Chun-Woong Park
Journal:  Int J Nanomedicine       Date:  2022-08-03

5.  Pure insulin nanoparticle agglomerates for pulmonary delivery.

Authors:  Mark M Bailey; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  Langmuir       Date:  2008-12-02       Impact factor: 3.882

6.  Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins.

Authors:  Laura J Peek; Lydia Roberts; Cory Berkland
Journal:  Langmuir       Date:  2008-08-05       Impact factor: 3.882

7.  Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.

Authors:  Bader M Jarai; Zachary Stillman; Lucas Attia; Gerald E Decker; Eric D Bloch; Catherine A Fromen
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-20       Impact factor: 9.229

8.  Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.

Authors:  Kavitha Koushik; Devender S Dhanda; Narayan P S Cheruvu; Uday B Kompella
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

9.  Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis.

Authors:  N A Cilfone; E Pienaar; G M Thurber; D E Kirschner; J J Linderman
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-11

10.  Encapsulating Polyethyleneimine-DNA Nanoplexes into PEGylated Biodegradable Microparticles Increases Transgene Expression In Vitro and Reduces Inflammatory Responses In Vivo.

Authors:  Treniece L Terry; Brittany E Givens; Andrea Adamcakova-Dodd; Peter S Thorne; Victor G J Rodgers; Aliasger K Salem
Journal:  AAPS PharmSciTech       Date:  2021-02-09       Impact factor: 3.246

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.